SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market volatility, driven by a combination of disappointing quarterly delivery figures, broader geopolitical instability in the Middle East, and active investor speculation regarding the company's valuation as a proxy for Elon Musk's wider ventures, including the upcoming SpaceX IPO. Community sentiment is deeply polarized, with traders aggressively debating whether to treat the stock as a distressed automotive manufacturer or a long-term play on AI and robotics, while many are actively using options to hedge or capitalize on the heightened price fluctuations.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Kelly Services is experiencing intense volatility driven by its extremely low float and active accumulation by institutional players and insiders, which has fueled widespread community speculation about a potential short squeeze. Traders are closely monitoring upcoming earnings and corporate conference calls as potential catalysts for further upward movement.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space (FJET) is experiencing heightened trading activity fueled by speculative interest in the broader space sector, specifically anticipation surrounding a potential SpaceX IPO and the company's recent operational updates at the Midland Air & Space Port. The stock remains a major talking point among retail investors, who are actively debating the company's long-term viability versus the potential for a volatile short squeeze given its small float and high short interest.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is rallying as the space sector gains momentum ahead of the Artemis II mission launch, with investors closely watching for impact on the broader orbital infrastructure market. The community remains highly active, debating the potential for a short squeeze while contrasting current mission optimism against lingering concerns over share offerings.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing intense volatility driven by conflicting signals between rising oil prices and algorithmic buying, leading to significant friction between bearish sentiment over geopolitical instability and bullish institutional accumulation. Community discussion is dominated by intense frustration over market manipulation, with retail traders debating whether the rapid price swings represent a sustainable rally or a deceptive trap ahead of the upcoming holiday weekend.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors position for upcoming earnings, buoyed by the integration of QNX technology into major automotive partnerships and strategic shifts toward software-defined vehicle infrastructure. Community sentiment remains polarized, with bullish long-term investors highlighting the growing royalty backlog and safety-critical moat as catalysts for a potential reversal, while skeptics remain focused on past revenue performance and management guidance.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is currently trading in a highly volatile, news-driven environment where investors are attempting to reconcile a significant spike in oil prices with a resilient equity market. Market participants remain deeply divided and cautious, with heavy debate focusing on whether the current price action is a genuine reversal or a manipulative bull trap designed to liquidate option premiums ahead of the long holiday weekend.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing heavy volatility as traders debate the sustainability of its parabolic rally following its S&P 500 inclusion and massive AI-driven infrastructure demand. The community is sharply divided between bulls citing mission-critical optical networking bottlenecks and bears warning of a potential liquidity trap or bubble valuation.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors monitor the early commercial launch of its FDA-approved therapy YARTEMLEA and await updates on potential milestone payments from its partnership with Novo Nordisk. Community discussion is heavily focused on the stock's undervaluation relative to its pipeline potential, the impact of significant short interest, and optimism surrounding upcoming European regulatory decisions.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors digest news of its controlling shareholder, Centurium Capital, acquiring the Blue Bottle Coffee brand, sparking speculation about a potential strategic pivot toward a multi-brand global platform. The community remains focused on the company's valuation, institutional accumulation by major firms like First Beijing Investment, and the ongoing debate regarding a long-anticipated relisting on a major U.S. exchange.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Due to continued war and strikes in the middle-east region, Brent crude is expected to cross $100 per barrel resulting in a bull run in oil stocks.&nbsp;</li><li>Pennzoil Quaker State Company DBA SOPUS Products, a wholly owned subsidiary of Shell USA, will sell Jiffy Lube International to an affiliate of Monomoy Capital Partners for $1.3 billion.&nbsp;</li><li>Shell will retain its Pennzoil Quaker State, Rotella and other Shell lubricants brands.</li></ul><p>U.S. listed shares of Shell jumped more than 2% on Monday helped by rising oil prices as well as the oil producer divesting Jiffy Lube International and Premium Velocity Auto for $1.3 billion.&nbsp;</p><p>Pennzoil Quaker State Company DBA SOPUS Products, a wholly owned subsidiary of Shell USA, Inc., that comprises Shell's United States lubricants business, has entered an agreement to sell Jiffy Lube International and its subsidiary Premium Velocity Auto business to an affiliate of Monomoy Capital Partners for $1.3 billion.&nbsp;</p><p>Shell is the leading deep-water operator and largest producer of oil and gas in the U.S. Gulf of America and the largest buyer of U.S. LNG.&nbsp;</p><h2 class="st-heading-2">Details</h2><p>The sale includes the Jiffy Lube brand and a network of franchised stores which are owned and operated by independent franchisees, in addition to franchised stores that are owned and operated by PVA.&nbsp;</p><p>Shell will retain its Pennzoil Quaker State, Rotella and other Shell lubricants brands, along with marketing, manufacturing and distribution of lubricants in the U.S. and Canada that serve consumer, commercial and industrial sectors.</p><p>"By capitalizing on a strong market opportunity, this divestment allows us to monetize an asset that is not central to Shell's lubricant's portfolio in the US and reinvest in opportunities that generate higher returns," said Machteld de Haan, President, Downstream, Renewables and Energy Solutions, Shell plc.</p><p>The transaction is expected to close in the second half of 2026, subject to regulatory approval and other closing conditions.</p><h2 class="st-heading-2">Oil Stocks In Focus&nbsp;</h2><p>Oil stocks have been in focus ever since war broke out between U.S.-Israel and Iran as it has led to blockade of a critical sea route of Strait of Hormuz through which almost 20% of global crude and LNG passes.&nbsp;</p><p>Due to continued war and strikes in the middle-east region, Brent crude is expected to cross $100 per barrel resulting in a bull run in oil stocks.&nbsp;</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment around SHEL trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;</p><p>Shares in the company have risen 17% year-to-date.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The Shell logo displayed at a Shell gas station in Edmonton, Alberta, Canada, on March 22, 2025. 

Shell Stock Hits 52-Week High – Here’s Why

Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 

Equity

Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 


<ul class="summary-bullets"><li>A Novo executive noted that many customers are unaware that the company already makes oral semaglutide for type 2 diabetes under the name Rybelsus, sparking the branding change.</li><li>Novo also said on Wednesday that it has filed an application with the FDA seeking approval for Ozempic tablets 25 mg in adults with type 2 diabetes.</li></ul><p>Danish drugmaker Novo Nordisk (NVO) said on Wednesday that the U.S. Food and Drug Administration has approved naming pill versions of some doses of its semaglutide for the treatment of type 2 diabetes as Ozempic pills.</p><p>Novo has been selling oral semaglutide for diabetes since 2019. However, it was previously called Rybelsus and was available at 3 mg, 7 mg, and 14 mg doses. Ozempic pills will be available in doses 1.5 mg, 4 mg, and 9 mg.</p><h2 class="st-heading-2">Why The Name Change?</h2><p>“By bringing the oral and injectable options under the Ozempic name, we’re helping make it clear that both contain semaglutide from Novo Nordisk and are approved to treat type 2 diabetes. The medicine and how it works remain the same; this simply makes the choices clearer to understand. There’s only One Ozempic…now in two presentations.” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916488">said</a> Ed Cinca, Senior Vice President of Marketing &amp; Patient Solutions at Novo Nordisk.</p><p>Cinca also noted that many customers are unaware that the company already makes oral semaglutide for type 2 diabetes under the name Rybelsus, sparking the branding change.</p><h2 class="st-heading-2">Launch Timeline</h2><p>The Ozempic pill will be launched in Q2 2026. The new formulation offers the same efficacy and safety profile as the originally approved formulation, the company said, while adding that the new doses were approved based on a bioequivalence study and the clinical trial program for Rybelsus tablets.</p><p>Novo got the approval of the U.S. Food and Drug Administration (FDA) for the Wegovy pill in December last year and launched it in early January. The weight-loss drug has had a great kickstart so far.</p><p>Novo also said on Wednesday that it has filed an application with the FDA seeking approval for Ozempic tablets 25 mg in adults with type 2 diabetes. The company now expects the agency to provide a decision on the application by 2026-end.</p><h2 class="st-heading-2">Flat Growth In Diabetes Segment</h2><p>Novo on Tuesday said that sales from its diabetes segment remained more-or-less flat on a reported basis in 2025 at DKK 207.11 billion while sales from its obesity segment increased 26% in Danish kroner to DKK 82.35 billion.</p><p>The company now expects adjusted sales to fall between 5% and 13%, and operating profit could decline by up to 13%. The company flagged concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVO stock stayed within the ‘bullish’ territory while message volume increased from ‘high’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> has fallen 43% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-asts-stocks-dip-amid-selloff-after-spacex-xai-merger-spurred-rally/cZbj9ElR4NO">RKLB, ASTS Stocks Dip Amid Selloff After SpaceX-xAI Merger Spurred Rally</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk To Launch Ozempic Pills Following Flat Growth In Diabetes Segment In 2025

The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg.

<ul class="summary-bullets"><li>The company flagged concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S.&nbsp;</li><li>The updated guidance comes on the heels of the company reporting full-year 2025 net sales of DKK309.06 billion, below an analyst estimate of DKK346.97 billion.</li><li>Novo’s sales from its diabetes segment remained more-or-less flat on a reported basis in 2025 at DKK207.11 billion while sales from its obesity segment increased 26% in Danish kroner to DKK82.35 billion.</li></ul><p>Shares of Danish drugmaker Novo Nordisk (NVO) plummeted 14% on Tuesday after the company said that it sees fiscal 2026 adjusted sales down 5% to 13% as it gears up to face pricing headwinds and a competitive market.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ml-eu.globenewswire.com/Resource/Download/7c7c1d6f-42c0-4e8f-821c-93ff9a0858c0">flagged </a>concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S.</p><p>Novo also sees adjusted operating profit fall as much as 13% in fiscal 2026 at constant exchange rates.</p><h2 class="st-heading-2">2025 Earnings</h2><p>The updated guidance comes on the heels of the company reporting full-year 2025 net sales of DKK309.06 billion ($48.94 billion), up 6% year-over-year on a reported basis, but below an analyst estimate of DKK346.97 billion.</p><p>Diluted earnings per share for the year came in at DKK23.03, up from DKK22.63 in 2024, and below a Wall Street estimate of DKK23.4.</p><p>Operating profit, meanwhile, decreased by 1% in Danish kroner to DKK127.66billion.</p><h2 class="st-heading-2">Executive Take</h2><p>CEO Mike Doustdar said that 2025 was a "challenging year” for the company.</p><p>“However, we are very encouraged by the promising early uptake from the US launch of Wegovy pill, and we remain confident in our ability to drive volume growth over the coming years,” Doustdar said.</p><p>“Also for this year, we look forward to regulatory decisions for next-generation treatments, such as Mim8 within haemophilia and CagriSema within obesity, as well as a number of exciting R&amp;D read-outs, including phase 3 read-outs for etavopivat and ziltivekimab," he added.</p><p>Novo got the approval of the U.S. Food and Drug Administration (FDA) for the Wegovy pill in December last year and launched it in early January. The drug has had a great kickstart so far.</p><p>In contrast, rival Eli Lilly and Co. (LLY) is still awaiting FDA approval on its oral weight-loss drug, giving Novo a few months of solid head start to cement its position in the market. However, Lilly is currently overtaking Novo in injectable weight loss drugs. &nbsp;</p><h2 class="st-heading-2">Blockbuster Drug Sales</h2><p>Novo said on Tuesday that sales from its diabetes segment remained more-or-less flat on a reported basis in 2025 at DKK 207.11 billion while sales from its obesity segment increased 26% in Danish kroner to DKK 82.35 billion.</p><p>Sales of the company’s blockbuster diabetes drug Ozempic came in at DKK130.11 billion for the year, while Wegovy sales came in at DKK79.11 billion.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVO stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> has dropped about 39% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-continues-to-rejig-lineup-in-run-up-to-vehicle-autonomy/cZb0GTWR4mS">Tesla Continues To Rejig Lineup In Run Up To Vehicle Autonomy</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p><i>Exchange Rate: DKK1= $0.16</i></p>

Novo Nordisk Shares Tumble On 2025 Earnings Miss, Weak Sales Forecast And Competition Concerns

The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.

<ul class="summary-bullets"><li>Keefe kept a price target of $3 up from $2.50 on the stock.&nbsp;</li><li>Keefe has concerns around Bitfarms's rising leverage and elevated capex.&nbsp;</li><li>The firm said it does not expect a leasing agreement to materialize for BITF until the second half of 2026.</li></ul><p>Shares of Bitfarms were down more than 1% during after hours of trading on Monday after an analyst raised liquidity concerns for the firm.&nbsp;</p><p>Shares in the company closed down 5.5% on Monday.&nbsp;</p><h2 class="st-heading-2">Liquidity Risks</h2><p>Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’ with a price target of $3, up from $2.50.&nbsp;</p><p>The firm said it does not expect a leasing agreement to materialize for the company until the second half of 2026. The stock already discounts a Sharon deal, said Keefe, which also has concerns around Bitfarms's rising leverage and elevated capex.&nbsp;</p><p>Keefe said it would get more constructive on the shares with greater clarity on the company's liquidity and 2026 capex.</p><h2 class="st-heading-2">Capital Raises</h2><p>Bitfarms in October had said that it has closed its offering of $588 million aggregate principal amount of 1.375% convertible senior notes due 2031. It said that Interest coupon will be payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2026.</p><p>Bitfarms had also converted a private debt facility for up to $300 million from Macquarie Group’s Commodities and Global Markets business, to an up to $300 million project-specific financing facility for the development of its data center campus in Panther Creek, Pennsylvania.</p><h2 class="st-heading-2">AI Data Center Push</h2><p>Bitfarm in 2024 had entered into the definitive lease agreement and assumed control of its newest data center in Sharon, Pennsylvania, initially announced on June 13, 2024.</p><p>This site represented Bitfarms’ first mega-site in the U.S. with access to up to 120 MW.&nbsp;</p><p>Bitfarms has planned to wind down its Bitcoin mining operations by 2027, and its transition will begin with its 18-megawatt site in Washington State.</p><h2 class="st-heading-2">LatAm Exit Deal</h2><p>BITF earlier in the month said it has entered into a share purchase agreement to sell its 70 MW site in Paso Pe, Paraguay, to the Sympatheia Power Fund (SPF), a crypto infrastructure fund managed by Singapore-based Hawksburn Capital.</p><p>The deal was valued at $30 million. Bitfarms would receive $9 million in cash upon closing, expected in Q1 2026, and up to $21 million over 10 months following closing, based on certain payment milestones, it had stated.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment around BITF trended in ‘bearish’ territory amid ‘low’ message volume.</p><p>Shares in the company have risen 65% over the past 12 months.&nbsp;<br>&nbsp;</p>

In this photo illustration, the Bitfarms Ltd logo is seen on a smartphone screen. 

Why Bitfarms Stock Is Down After Hours?

Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’. 

<ul class="summary-bullets"><li>Reuters noted that oral Wegovy’s debut is stronger than observed with Novo’s injectable Wegovy or its rival Eli Lilly and Company’s Zepbound.&nbsp;</li><li>Novo’s rival Lilly, meanwhile, is looking forward to getting FDA approval for its oral obesity drug Orforglipron by April.</li></ul><p>Danish drugmaker Novo Nordisk’s (NVO) Wegovy pill reportedly hit over 18,000 U.S. prescriptions in the first full week after its launch, marking a strong start for the oral weight-loss pill. &nbsp;</p><p>Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novos-wegovy-pill-tracks-18410-prescriptions-first-full-week-since-launch-2026-01-23/">reported</a> on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16. As per the report, this is a stronger debut than observed with Novo’s injectable Wegovy or its rival Eli Lilly and Company’s Zepbound.</p><p>Last week, it was reported that the Wegovy pill hit 3,071 U.S. prescriptions in just the first four days after its launch on Jan 5.</p><p>NVO shares traded marginally in the green on Friday at the time of writing.</p><h2 class="st-heading-2">Wegovy Pill Approval</h2><p>Oral obesity pills are expected to be the next major innovation in the obesity market, doing away with needles and offering customers more flexibility and ease.</p><p>The U.S. Food and Drug Administration (FDA) approved the Wegovy pill to reduce body weight and maintain weight reduction for a longer term in December.</p><p>The Wegovy pill is now the first FDA-approved oral GLP-1 class drug for weight management and marks a crucial step forward for the company in its ongoing efforts to protect market share from rival Eli Lilly, whose injectable GLP-1 drug Zepbound is fast taking over Wegovy’s market dominance. The company launched the Wegovy pill earlier this month, starting at $149 a month.</p><p>Novo’s rival Lilly, meanwhile, is looking forward to getting FDA approval for its oral obesity drug Orforglipron by April. Novo now has a few months’ head start against Lilly to cement its customer base.</p><p>On Thursday, Goldman Sachs raised its price target on Novo Nordisk to DKK 436 from DKK 352 while keeping a ‘Buy’ rating on the shares. The firm believes investor focus in the first half of 2026 will be the launch for Novo's Wegovy pill. The weight loss pill should contribute to positive earnings momentum in the near term, the analyst told investors, as per TheFly.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVO stock stayed within the ‘bullish’ territory, while message volume fell from ‘high’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/NVO">NVO shares</a> have fallen 23% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/bhc-stock-plummets-on-failed-liver-cirrhosis-trial/cmyRgOmR4gz">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week

Reuters reported on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16.

<ul class="summary-bullets"><li>CEO Thomas J. Appio said that the company is “disappointed in the results.”</li><li>The experimental therapy, however, was safe and well-tolerated, the company said.</li><li>Rifaximin is already approved in the U.S. and marketed as Xifaxan.</li></ul><p>Shares of Bausch Health Companies Inc. (BHC) fell 10% on Friday after the company said that its late-stage program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis failed to meet its primary goal.</p><p>The clinical program <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bauschhealth.com/news-releases/2026/01-23-2026-124516159">evaluated</a> rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes. The program consisted of two global trials involving more than 1000 patients.</p><p>Hepatic encephalopathy is a serious brain dysfunction caused by liver failure, where the liver can't remove toxins from the blood, allowing them to build up and affect the brain, causing confusion, personality changes, slurred speech, and lethargy, potentially leading to coma.</p><h2 class="st-heading-2">Executive Takeaway</h2><p>CEO Thomas J. Appio said that the company is “disappointed in the results.” The experimental therapy, however, was safe and well-tolerated, the company said.</p><p>“We are currently reviewing the full dataset to determine potential new development opportunities," he said while adding that the company remains committed to bringing new treatments to patients across hepatology and other therapeutic areas.</p><p>Rifaximin is already approved in the U.S. and marketed as Xifaxan which is slated to lose exclusivity in 2028. The recent trials were evaluating a new variant of the compound.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around BHC stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘high’ to ‘extremely high’ levels.</p><p>A Stocktwits user expressed anticipation for the company’s quarterly report in February, saying the company “lost &nbsp;a &nbsp;Battle but not &nbsp;the &nbsp;war.”</p><p><stembedurl>https://www.stocktwits.com/Valmaro/message/642700352</stembedurl></p><p>Another user, however, opined that the trial failure is “a serious blow” to the company’s future prospects.</p><p><stembedurl>https://www.stocktwits.com/Contrarian_Dan/message/642693387</stembedurl></p><p><a href="https://stocktwits.com/symbol/BHC">BHC stock</a> has dropped 24% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-market-share-dives-in-ev-stronghold-california-in-2025-paving-way-for-asian-rivals-growth/cmUCgvWR4X8">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration, the Bausch Health logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.

<ul class="summary-bullets"><li>Novo and Aspect have been collaborating since 2023 to develop cellular medicines.</li><li>Under the deal, Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk and will now lead their development.&nbsp;</li><li>Novo, in turn, will make an additional equity investment in Aspect and provide research funding.</li></ul><p>Danish drugmaker Novo Nordisk (NVO) said on Tuesday that it is looking to develop new medicines for diabetes as part of its new partnership with Canadian biotech firm Aspect Biosystems.</p><p>Novo and Aspect have been collaborating since 2023 to develop cellular medicines. The companies <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916478">said</a> that the new partnership phase builds on the momentum achieved in the existing collaboration.</p><h2 class="st-heading-2">Deal Terms</h2><p>Under the deal, Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk. This refers to technology allowing for making insulin-producing cells from stem cells for diabetes treatment and modifying cells to evade the immune system, thereby avoiding immune rejection. The privately-held company will now lead its development, manufacturing and commercialisation.</p><p>Novo, in turn, will make an additional equity investment in Aspect and provide research funding. It will also retain rights to expand its role in late-stage development and commercialisation as well. &nbsp;</p><p>Novo Nordisk will be eligible to receive royalties and milestone payments on future product sales from Aspect. However, the companies didn’t provide the financial terms of the agreement.</p><h2 class="st-heading-2">Novo On Lookout For More</h2><p>Last week, Novo said it is on the lookout for merger and acquisition deals to boost its drug portfolio.</p><p>Novo’s CEO Mike Doustdar said during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets, and companies that are complementary to its portfolio. Doustdar said that the company can afford any amount for an asset, provided it is worth it.</p><p>Novo’s best-selling drugs now include Wegovy and Ozempic for weight loss and diabetes, respectively.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVO stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/NVO">NVO shares</a> have fallen 25% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lululemon-stock-slips-after-reportedly-removing-see-through-leggings-from-website/cmUuHw8R4OO">Lululemon Stock Slips 6% After Reportedly Removing “See-Through” Leggings From Website</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic

Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.

<ul class="summary-bullets"><li>While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival.&nbsp;</li><li>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma.</li><li>The company said it now intends to engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie.</li></ul><p><br>Genmab A/S (GMAB) said on Friday that its late-stage trial evaluating drug Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.</p><p>While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/16/3220513/0/en/Genmab-Announces-Topline-Results-for-Epcoritamab-DuoBody-CD3xCD20-from-Phase-3-EPCORE-DLBCL-1-Trial-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL.html">said.</a> While progression-free survival represents the time a patient lives with cancer without it getting worse or dying, overall survival is the length of time from diagnosis or treatment start until death from any cause.</p><h2 class="st-heading-2">Study Details</h2><p>Genmab enrolled 483 patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma in the trial who had undergone at least one prior line of therapy. These patients were ineligible for high-dose chemotherapy, the company said.</p><p>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma, a blood cancer involving rapid growth of large B-lymphocytes in the lymphatic system, lymph nodes, and other organs, often presenting as fast-growing masses or swollen nodes with symptoms like fever, night sweats, and weight loss. According to Genmab, there are approximately 25,000 new cases of DLBCL diagnosed each year in the U.S.</p><p>The company said it intends to now engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie. Epcoritamab, being co-developed by Genmab and AbbVie, is already approved in several countries for the treatment of certain lymphomas.</p><p>Shares of GMAB fell 5% at the time of writing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around GMAB stock stayed within the ‘bearish’ territory coupled with ‘high’ message volume.</p><p>Meanwhile, sentiment around ABBV shares rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.</p><p>A Stocktwits user sees GMAB stock plummet down to $20 from current levels.</p><p><stembedurl>https://www.stocktwits.com/nopumpdump/message/642093162</stembedurl></p><p><a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> has gained 51% over the past 12 months while <a href="https://stocktwits.com/symbol/ABBV">ABBV shares</a> added 24%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvo-shares-rise-on-strong-kickstart-for-wegoy-pill-in-us/cmUlCCgR4Bq">NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Genmab logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said.

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory diffuse large B-cell lymphoma, the company said.


<ul class="summary-bullets"><li>If approved, Ianalumab could become the first targeted treatment for Sjögren’s disease.&nbsp;</li><li>The Breakthrough Therapy designation was granted to Novartis on the basis of clinical evidence supporting the drug’s potential.</li><li>In Novartis’ late-stage trials evaluating the efficacy and safety of Ianalumab in patients with Sjögren’s disease, the drug delivered a clinically meaningful benefit.</li></ul><p>Shares of Novartis (NVS) rose 1% on Friday after the U.S. Food and Drug Administration granted its drug Ianalumab a breakthrough therapy designation in the treatment of Sjögren’s disease.</p><p>Sjögren’s disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body. It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.</p><p>According to Novartis, 50% of people with Sjögren’s are undiagnosed, though it is the second-most prevalent rheumatic autoimmune disease.</p><p>Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval. If approved, it could become the first targeted treatment for Sjögren’s disease, as per Novartis.</p><h2 class="st-heading-2">The Designation</h2><p>The Breakthrough Therapy designation, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-sjogrens-disease">granted</a> to Novartis on the basis of clinical evidence supporting the drug’s potential, is intended to expedite the review of medicines that treat a serious or life-threatening condition. Ianalumab was previously awarded the FDA’s Fast Track designation in 2016.</p><p>In Novartis’ late-stage trials that evaluated the efficacy and safety of Ianalumab in patients with Sjögren’s disease, the drug delivered a clinically meaningful benefit, showing improvement in disease activity and reductions in patient burden. Further, the drug demonstrated a favorable safety profile with an overall incidence of adverse events comparable to placebo.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NVS stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/NVS">NVS stock</a> has gained nearly 48% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvo-shares-rise-on-strong-kickstart-for-wegoy-pill-in-us/cmUlCCgR4Bq">NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment

Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval.

<ul class="summary-bullets"><li>The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment.</li><li>Separately, AstraZeneca announced that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of lung cancer.</li></ul><p>Pharmaceutical giant AstraZeneca (AZN) has purchased Boston-based biomedical AI company Modella AI for an undisclosed sum, according to a statement from the startup on Tuesday.</p><p>Modella <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260113561240/en/Modella-AI-Announces-Acquisition-by-AstraZeneca-to-Advance-AI-Driven-Oncology-RD-at-Global-Scale">said</a> that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.</p><p>The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment. This would allow for the generation of new insights and allow for greater automation across workflows, the company said.</p><p>Shares of AZN traded marginally in the green at the time of writing.</p><h2 class="st-heading-2">Partnership To Acquisition</h2><p>Modella announced a multi-year deal with AstraZeneca in 2025 aimed at integrating its generative and agentic AI platform into AstraZeneca’s oncology research and development organization.</p><p>The collaboration was aimed at supporting efforts to accelerate clinical development and enhancing biomarker discovery.</p><h2 class="st-heading-2">First Patient Dosing In New Late-Stage Trial</h2><p>Separately, AstraZeneca announced earlier on Tuesday that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of locally advanced or metastatic nonsquamous non-small cell lung cancer. Lung cancer is the most common cancer globally.</p><p>Datroway, meanwhile, is a cancer drug jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around AZN stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.</p><p>A Stocktwits user opined that AstraZeneca must try to acquire smaller drugmaker Omeros Corp.</p><p><stembedurl>https://www.stocktwits.com/resq1/message/641646825</stembedurl></p><p><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> has gained 43% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fund-manager-flags-concerns-about-tesla-dwindling-delivery-numbers-high-pe-ratio/cmUXXNkR4Ia">Fund Manager Flags Concerns About Tesla’s Dwindling Delivery Numbers, Notes High P/E Ratio</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio. 

Current Price	$34.18
Prev Close	$34.42
Open	$33.68
Dividend Yield	N/A
50-Day Moving Average	$35.05
Beta	N/A
Avg. Volume	1.11M
PE Ratio	N/A

52-Week High	$37.13
52-Week Low	$23.16
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

DFAX
Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DFAX News

DFAXDimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF